<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HC166D54D77DC41DF899BB1B004A02781" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 4918 IH: Speeding Access to Already Approved Pharmaceuticals Act of 2014</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2014-06-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4918</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140619">June 19, 2014</action-date>
			<action-desc><sponsor name-id="S001187">Mr. Stivers</sponsor> (for himself and <cosponsor name-id="R000577">Mr. Ryan of Ohio</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved
			 for marketing in the European Union.</official-title>
	</form>
	<legis-body id="H3CB0F1F30977424DB01A9A18FCEAD3A9" style="OLC">
		<section id="HD54EAD64F9C94DFE9B90AB07AF95AFC1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Speeding Access to Already Approved Pharmaceuticals Act of 2014</short-title></quote>.</text>
		</section><section id="HDF462473014A48958A420C96024878A9"><enum>2.</enum><header>Expedited review of EU-approved pharmaceuticals</header>
			<subsection id="HF3494B70ABC545F4BEDB040711CBB686"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 506 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>) is amended by adding at the
			 end the following:</text>
				<quoted-block display-inline="no-display-inline" id="HD4C5911A39CC43BF9A97EACFB6B14297" style="OLC">
					<subsection id="H1B29FA3875174928A7134909DE2A4B71"><enum>(g)</enum><header>EU-Approved pharmaceuticals</header>
						<paragraph id="H98B2D7F28B774B6192F4CAC77D6F2B89"><enum>(1)</enum><header>Expedited review</header><text>Beginning not later than 90 days after a new pharmaceutical is approved for marketing in the
			 European Union, the Secretary shall, at the request of the sponsor of the
			 pharmaceutical, facilitate the development and expedite the review of such
			 new pharmaceutical under section 505 or 515 of this Act or section 351 of
			 the Public Health Service Act, as appropriate.</text>
						</paragraph><paragraph id="HB314F8B2F06240D8AE1C833DBD73E424"><enum>(2)</enum><header>Definition</header><text>In this subsection, the term <term>pharmaceutical</term> means a drug (including a biological product) or a device.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection><subsection id="H4C9C7721F3744C6DA233B39DAA4F6C4C"><enum>(b)</enum><header>Technical correction</header><text display-inline="yes-display-inline">Subsection (f) (relating to awareness efforts) of section 506 of the Federal Food, Drug, and
			 Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>) is hereby moved so as to follow subsection
			 (e) (relating to construction) of such section 506.</text>
			</subsection></section></legis-body>
</bill>


